![Global Psoriasis Drugs Market Size Global Psoriasis Drugs Market Summary](https://s3.mordorintelligence.com/psoriasis-drugs-market/1735817097537-psoriasis-drugs-market-Market-Summary.png)
Study Period | 2020 - 2030 |
Market Size (2025) | USD 20 Billion |
Market Size (2030) | USD 30.32 Billion |
CAGR (2025 - 2030) | 8.68 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Market Concentration | Medium |
Major Players![]() *Disclaimer: Major Players sorted in no particular order |
Global Psoriasis Drugs Market Analysis
The Global Psoriasis Drugs Market size is estimated at USD 20 billion in 2025, and is expected to reach USD 30.32 billion by 2030, at a CAGR of 8.68% during the forecast period (2025-2030).
The market's growth is primarily due to an increasing disease burden and demand for psoriasis medicines in emerging economies and an increase in psoriasis research and pipeline drugs.
The high burden of psoriasis worldwide is expected to boost the demand for its drugs, thus contributing to market growth. For instance, the data published by the National Psoriasis Foundation in August 2024 mentioned that over 8 million individuals in the United States and 125 million across the globe were affected by psoriasis in 2023. Thus, such a high burden of psoriasis among the population is anticipated to fuel the demand for psoriasis drugs and is expected to propel the market growth
Novel drugs with oral administration are opening avenues for needle-averse patients. For instance, in November 2024, Johnson & Johnson Services, Inc. showcased interim findings from the PsABIOnd study, which evaluated the effects of TREMFYA and IL-17 inhibitors on how patients perceive the impact of psoriatic arthritis (PsA). The study revealed significant reductions in joint pain, skin symptoms, and overall disease activity, underscoring the beneficial effects of TREMFYA on PsA. Additionally, in September 2024, Bristol Myers Squibb introduced positive results from the Phase 3b/4 PSORIATYK SCALP trial, which assessed the efficacy of Sotyktu (deucravacitinib) for treating patients with moderate to severe scalp psoriasis, even in those with milder overall psoriasis. The trial also achieved important secondary endpoints at week 16, revealed that a significantly more significant percentage of patients experienced at least a 90% improvement in their psoriasis. Thus, key market players are involved in various business strategies, such as product approvals and positive clinical trials, to expand their product portfolios and gain a competitive edge, which is anticipated to boost market growth.
Therefore, the market is expected to register a high growth rate during the forecast period due to the abovementioned factors, such as the high burden of psoriasis and the market player initiatives. However, the adverse side effects of most of the existing medications and the high cost of treatment are expected to hamper the market's growth.
Global Psoriasis Drugs Market Trends
Interleukin Inhibitors Segment are Expected to Register a High CAGR Over the Forecast Period
Interleukin inhibitors are anticipated to witness the fastest growth during the forecast period. The factors aiding interleukin inhibitors are their improved safety and efficacy compared to other classes of psoriasis drugs, consistently leading to increased patient adoption. Major approved antibodies targeting interleukins include Taltz (Ixekizumab), Cosentyx (Secukinumab), Siliq (Brodalumab), Tremfya (Guselkumab), Ilumya (Tildrakizumab), and SKYRIZI (Risankizumab) and others.
Drug approvals by regulatory authorities are also contributing to the segment's growth. For instance, in August 2023, Akeso Inc. revealed that the National Center for Drug Evaluation of the State Drug Administration of the People's Republic of China (NMPA CDE) accepted the New Drug Application (NDA) for its fully human IgG1 monoclonal antibody, ebdarokimab (IL-12/IL-23, AK101), intended for the treatment of adult patients with moderate-to-severe plaque-type psoriasis. This development is expected to strengthen the interleukin inhibitors segment within the psoriasis drugs market, as such advancements contribute to the growing adoption of targeted therapies.
Additionally, in May 2023, Xencor revealed the clinical findings from a phase-Ia single-ascending dose trial of XmAb564, a monovalent Interleukin-2 (IL-2) Fc fusion protein, involving healthy adult participants. The company is actively enrolling patients for the phase-Ib multiple-ascending dose study in individuals with atopic dermatitis and psoriasis and is expected to finish dose escalation in the psoriasis cohorts by early 2024. Such approvals and launches are contributing to the growth of the market segment.
Thus, owing to the abovementioned factors, the market segment is expected to show significant growth over the forecast period.
![Global Psoriasis Drugs Market Trends Global Psoriasis Drugs Market: Number of Clinical Studies for Psoriasis, By Phase, Global, As of November 2024](https://s3.mordorintelligence.com/psoriasis-drugs-market/1736417099921-psoriasis-drugs-market-Number-of-Clinical-Studies-for-Psoriasis-By-Phase-Global-As-of-November-2024.png)
North America is Expected to Hold a Significant Market Share in the Psoriasis Dugs Market in the Forecast Period
The North American region is expected to occupy the largest market share in the psoriasis drugs market during the forecast period due to an increase in disease burden and demand for psoriasis medicines, increasing use of combination therapies, and an upsurge in psoriasis research and pipeline drugs. Other factors that will propel the market's growth include favorable government initiatives and developed healthcare infrastructure.
Due to the high prevalence of psoriasis in the North American region, the demand for psoriasis drugs is likely to rise, thus fueling the market's growth in the region. For instance, as per the article published in the JAMA Network Open Journal in April 2023, the prevalence of psoriasis in the United States was 1.4%, which was approximately seven times higher than the estimated prevalence in China, which stood at 0.21%. Hence, the high burden of psoriasis in the North American region is anticipated to drive the demand for its drugs and propel the market's growth.
Moreover, market player initiatives such as product approvals and new drug launches are expected to contribute to the market's growth in the region. For instance, in August 2024, Amgen revealed that Otezla (apremilast) was now approved for pediatric use in the United States to treat moderate to severe plaque psoriasis. Additionally, in July 2024, Arcutis Biotherapeutics introduced that the United States Food and Drug Administration (FDA) accepted the supplemental New Drug Application (sNDA) for roflumilast foam 0.3% (Zoryve), intended for treating scalp and body psoriasis in adults and adolescents aged 12 and older. Thus, new drug approvals and product launches in the North American market may further propel the market's growth in this region.
Thus, due to the aforementioned factors, such as the high burden of psoriasis and new drug approvals and product launches, the market's growth in the region is expected to accelerate over the forecast period.
![Global Psoriasis Drugs Market Trends Psoriasis Drugs Market - Growth Rate by Region](https://s3.mordorintelligence.com/psoriasis-drugs-market/1736417115159-psoriasis-drugs-market-Psoriasis-Drugs-Market---Growth-Rate-by-Region.png)
Global Psoriasis Drugs Industry Overview
The psoriasis drugs market is moderately competitive and consists of several key players. Concerning the market share, few of the key players currently dominate the market. Companies are focusing on business expansion in developing regions or emerging markets, such as India, China, and South Korea, by adopting strategies, including alliances and acquisitions, to develop novel products. Some of the major players operating in the market include Johnson and Johnson Services Inc., Pfizer Inc., Amgen Inc., Eli Lilly and Company, and Novartis AG, among others.
Global Psoriasis Drugs Market Leaders
-
Eli Lilly and Company
-
Pfizer Inc.
-
Novartis AG
-
Amgen Inc.
-
Johnson & Johnson Services, Inc.
- *Disclaimer: Major Players sorted in no particular order
![Global Psoriasis Drugs Market Concentration Global Psoriasis Drugs Market Concentration](https://s3.mordorintelligence.com/psoriasis-drugs-market/1731914162016-psoriasis-drugs-market-psoriasis-drugs-market-Competitive-Landscape.png)
Global Psoriasis Drugs Market News
- November 2024: UCB S.A. presented new two-year data validating a continuous clinical response for bimekizumab-bkzx, an inhibitor of IL-17A and IL-17F, in adults diagnosed with active psoriatic arthritis (PsA) with observable signs of reduction in inflammation.
- September 2024: Organon and Dermavant Sciences Ltd. finalized an agreement in which Organon will acquire Dermavant, a company under Roivant that specializes in the development and commercialization of cutting-edge therapeutics for immuno-dermatology. Dermavant's innovative product approved by the United States Food and Drug Administration (FDA), VTAMA (tapinarof) cream, 1%, for the topical treatment of adults with mild, moderate, and severe plaque psoriasis. By combining Dermavant’s robust dermatology commercial and field medical teams in the United States with Organon’s capabilities in market access, regulatory proficiency, and global commercial presence.
Global Psoriasis Drugs Industry Segmentation
As per the scope of the report, psoriasis is a genetic condition that may or may not be present at birth but can also be triggered by certain environmental and genetic factors. Factors such as the changing lifestyles of people and their increased inclination toward alcohol consumption and smoking, unhealthy diets, and sedentary living are making people more prone to this condition. The psoriasis drugs market is segmented by type of treatment, mechanism of action, route of administration and geography. By type of treatment, the market is segmented into biologic drugs, small molecule systemic drugs, and tropical therapies. By mechanism of action, the market is segmented into TNF alpha inhibitors, PDE4 inhibitors, interleukin inhibitors, and other mechanisms of action. Other mechanism of action will include anti CD-6 monoclonal antibodies, JAK inhibitors and others. By route of administration, the market is segmented into oral, parenteral, and topical. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. For each segment, the market size is provided in terms of USD value.
By Type of Treatment | Biologic Drugs | ||
Small Molecule Systemic Drugs | |||
Tropical Therapies | |||
By Mechanism of Action | TNF Alpha Inhibitors | ||
PDE4 Inhibitors | |||
Interleukin Inhibitors | |||
Other Mechanisms of Action | |||
By Route of Administration | Oral | ||
Parenteral | |||
Topical | |||
Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
Japan | |||
India | |||
Australia | |||
South Korea | |||
Rest of Asia-Pacific | |||
Middle-East and Africa | GCC | ||
South Africa | |||
Rest of Middle-East and Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Global Psoriasis Drugs Market Research FAQs
How big is the Global Psoriasis Drugs Market?
The Global Psoriasis Drugs Market size is expected to reach USD 20 billion in 2025 and grow at a CAGR of 8.68% to reach USD 30.32 billion by 2030.
What is the current Global Psoriasis Drugs Market size?
In 2025, the Global Psoriasis Drugs Market size is expected to reach USD 20 billion.
Who are the key players in Global Psoriasis Drugs Market?
Eli Lilly and Company, Pfizer Inc., Novartis AG, Amgen Inc. and Johnson & Johnson Services, Inc. are the major companies operating in the Global Psoriasis Drugs Market.
Which is the fastest growing region in Global Psoriasis Drugs Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Global Psoriasis Drugs Market?
In 2025, the North America accounts for the largest market share in Global Psoriasis Drugs Market.
What years does this Global Psoriasis Drugs Market cover, and what was the market size in 2024?
In 2024, the Global Psoriasis Drugs Market size was estimated at USD 18.26 billion. The report covers the Global Psoriasis Drugs Market historical market size for years: 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Psoriasis Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.